About Chinook Therapeutics, Inc.Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases.

BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy. VP, Investor Relations & Corporate Communications

V5T 4T5 Effective as of the closing of the merger, the board of directors of Chinook will be comprised of seven directors: Eric Dobmeier, president and chief executive officer of Chinook Therapeutics; Jerel Davis, Ph.D., managing director at Versant Ventures; Srini Akkaraju, M.D., Ph.D., managing general partner at Samsara BioCapital; William M. Greenman, president and chief executive officer of Cerus Corporation; Ross Haghighat, founder, chairman and managing partner of Triton Systems, Inc.; Michelle Griffin, director and audit committee chair for Adaptive Biotechnologies, Acer Therapeutics and HTG Molecular Diagnostics, Inc.; and Dolca Thomas, M.D., chief medical officer of Principia Biopharma, Inc. MTS Health Partners acted as exclusive financial advisor to Chinook and Fenwick & West LLP served as legal counsel to Chinook for the merger.

© 1985 - 2020 BioSpace.com. Another way to prevent getting this page in the future is to use Privacy Pass. All rights reserved. If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. As part of the financing, Chinook’s existing investors, Versant Ventures, Apple Tree Partners and Samsara BioCapital, purchased $25 million in Chinook common stock on the same terms as the new investors.

When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing. Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at ASN’s Kidney Week 2020 Reimagined from October 22-25, 2020. Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined, Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined, Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing, Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease, Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement, Aduro and Chinook to Merge, Launch New Clinical Trials for their Pipeline, Chinook Therapeutics to Present at the Jefferies Virtual Healthcare Conference. Advancement of additional research and discovery programs focused on the treatment of rare, severe chronic kidney diseases. SVB Leerink acted as exclusive financial advisor to Aduro and Latham & Watkins LLP served as legal counsel to Aduro for the merger. Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced three poster presentations and one oral presentation at ASN’s Kidney Week 2020 Reimagined. Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. Performance & security by Cloudflare, Please complete the security check to access. Chinook seeks to build its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

RedHill Biopharma has gained the rights to Movantik (naloxegol) in Israel from AstraZeneca.

Many of these risks are described in greater detail in the proxy statement/prospectus filed by Aduro with the SEC relating to the merger.

Canada.

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware. As previously announced, the $115 million private placement financing includes participation from new investors EcoR1 Capital, OrbiMed Advisors, funds managed by Rock Springs Capital, Fidelity Management and Research Company LLC, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech and other top-tier healthcare investors. Cloudflare Ray ID: 5e74e1f47df89f94 The new company, which was founded earlier this year, will take a similar approach to treat kidney disease that oncologists have taken with cancer. Chinook Therapeuticsinvestors@chinooktx.commedia@chinooktx.com, Vice President Chinook’s Series A funding was led by founding investor Versant Ventures. Vancouver and Seattle-based Chinook Therapeutics Closes Merger With Aduro Biotech and Completes $115 Million Private Placement Financing. Movantik is approved in Israel, under the brand name Moventig, for the treatment of opioid … Vanouver, BC, October 21, 2020--Chinook Therapeutics, Inc.(NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, has announced the …

In addition, Chinook is advancing advance CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc., a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a $106 million private placement financing, Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. “With a strong cash position, a promising pipeline and our dedication to treating patients with debilitating kidney diseases, we are well positioned to achieve value-generating milestones and build a leading company in the kidney disease space.”. Your IP: 184.168.147.124

• Chinook Therapeutics, Inc., a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a $106 million private placement financing, – Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook’s Existing Investors – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months – Companies to H. Chinook Therapeutics, Inc. (“Chinook”), a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, President and Chief Executive Officer, will present an overview of the company and its pipeline at the Jefferies Virtual Healthcare Conference at 3:30 p.m. EDT on Wednesday, June 3, 2020.

BC Effective as of the closing of the merger, Chinook has over $275 million in operating capital to advance its kidney disease programs. Vancouver Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease. Contact:Noopur Liffick

Chinook launched less than two years ago to develop precision medicines for chronic kidney diseases and will have three drugs in the clinic in 2021, including a Phase III candidate for IgA nephropathy. • SVB Leerink acted as lead placement agent and Evercore Group L.L.C. British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.

Prior Chinook stockholders collectively own approximately 39.5% of the combined company, prior Aduro stockholders collectively own approximately 39.9% of the combined company and investors in the Chinook private placement financing collectively own approximately 20.6% of the combined company. Chinook’s lead program is atrasentan, an investigational Phase 3-ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. You may need to download version 2.0 now from the Chrome Web Store. Powered by Madgex Job Board Software. Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”, VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the closing of its merger with Aduro Biotech, Inc. and $115 million private placement financing. Planned Phase 3 and Phase 2 trials of atrasentan, an investigational selective endothelin receptor antagonist, in development for the treatment of IgA nephropathy and other primary glomerular diseases; An ongoing Phase 1b and future clinical trials of BION-1301, an investigational humanized monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, in development for the treatment of IgA nephropathy; A planned Phase 1 trial of CHK-336, an investigational small molecule, in preclinical development for the treatment of an ultra-rare orphan kidney disease; and. “Chinook’s merger with Aduro and entry into the public market is a transformative event that will propel the development of our atrasentan, BION-1301 and CHK-336 programs, and drive forward our research and discovery programs for other rare, severe chronic kidney diseases with large unmet medical needs,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways.